Display options
Cite
Fan J, Liang R. Quantitative assessment of TLR4 gene polymorphisms and T2DM risk: A meta-analysis. Mol Genet Genomic Med. 2020;8(10):e1466doi: 10.1002/mgg3.1466.
Fan, J., & Liang, R. (2020). Quantitative assessment of TLR4 gene polymorphisms and T2DM risk: A meta-analysis. Molecular genetics & genomic medicine, 8(10), e1466. https://doi.org/10.1002/mgg3.1466
Fan, Jinzhuo, and Liang, Renxian. "Quantitative assessment of TLR4 gene polymorphisms and T2DM risk: A meta-analysis." Molecular genetics & genomic medicine vol. 8,10 (2020): e1466. doi: https://doi.org/10.1002/mgg3.1466
Fan J, Liang R. Quantitative assessment of TLR4 gene polymorphisms and T2DM risk: A meta-analysis. Mol Genet Genomic Med. 2020 Oct;8(10):e1466. doi: 10.1002/mgg3.1466. Epub 2020 Aug 21. PMID: 32822111; PMCID: PMC7549608.
Copy Download .nbib Format: NLM
Share it on

Mol Genet Genomic Med. 2020 Oct;8(10):e1466. doi: 10.1002/mgg3.1466. Epub 2020 Aug 21.

Quantitative assessment of TLR4 gene polymorphisms and T2DM risk: A meta-analysis.

Molecular genetics & genomic medicine

Jinzhuo Fan, Renxian Liang

Affiliations

  1. Department of Traditional Chinese Medicine and Acupuncture, Hainan Hospital of General Hospital of Chinese PLA, Sanya, China.
  2. Department of Cardiovascular and Endocrinology, Beibei Traditional Chinese Medicine Hospital, Chongqing, China.

PMID: 32822111 PMCID: PMC7549608 DOI: 10.1002/mgg3.1466

Abstract

BACKGROUND: Numerous studies have evaluated the association between TLR4 gene polymorphisms and T2DM risk. However, the findings were inconsistent and controversial.

METHODS: In order to drive a more precise estimation, we carried out a meta-analysis based on 41 studies involving 23,250 cases and 24,760 controls. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of association.

RESULTS: Our meta-analysis provides evidence that rs4986790 polymorphism was associated with an increased risk of T2DM in Asian (AG vs. AA, OR = 1.23, 95% CI = 1.01-1.50, p = 0.042; G vs. A, OR = 1.21, 95% CI = 1.01-1.44, p = 0.041). Rs4986791 polymorphism was related to an increased risk of T2DM both in Asian (AG vs. AA, OR = 1.76, 95% CI = 1.11-2.80, p = 0.017; G vs. A, OR = 1.63, 95% CI = 1.04-2.55, p = 0.034) and Caucasian (GG vs. AA, OR = 2.42, 95% CI = 1.23-4.75, p = 0.010). Rs11536889 polymorphism may have a protective effect on T2DM in Chinese populations (CC vs. GG, OR = 0.62, 95% CI = 0.40-0.96, p = 0.031; GC vs. GG, OR = 0.77, 95% CI = 0.61-0.98, p = 0.034; CC vs. GC/GG, OR = 0.81, 95% CI = 0.69-0.96, p = 0.013; C vs. G, OR = 0.76, 95% CI = 0.59-0.97, p = 0.027), whereas rs1927911 may have no impact.

CONCLUSIONS: These findings supported that rs4986790, rs4986791, and rs11536889 may contribute to the risk of T2DM.

© 2020 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.

Keywords: T2DM; TLR4; meta-analysis; polymorphism; risk

References

  1. Diabetologia. 1998 Oct;41(10):1241-8 - PubMed
  2. Inflamm Res. 2019 Sep;68(9):801-814 - PubMed
  3. Hum Immunol. 2009 Feb;70(2):121-4 - PubMed
  4. Pharmacogenet Genomics. 2010 Sep;20(9):544-52 - PubMed
  5. Diabetes Res Clin Pract. 2018 Apr;138:271-281 - PubMed
  6. Mol Biol Rep. 2013 Apr;40(4):3015-20 - PubMed
  7. Scand J Clin Lab Invest. 2006;66(8):667-75 - PubMed
  8. Diabetes Res Clin Pract. 2015 Mar;107(3):338-47 - PubMed
  9. Acta Endocrinol (Buchar). 2019 Jan-Mar;-5(1):32-38 - PubMed
  10. Diabetes. 2003 Nov;52(11):2861-4 - PubMed
  11. Diabetologia. 1992 Nov;35(11):1060-7 - PubMed
  12. J Diabetes. 2015 Jul;7(4):485-92 - PubMed
  13. APMIS. 2013 Jul;121(7):605-11 - PubMed
  14. Diabetes Res Clin Pract. 2016 Jun;116:7-13 - PubMed
  15. J Natl Cancer Inst. 1959 Apr;22(4):719-48 - PubMed
  16. Inflammation. 2013 Feb;36(1):251-7 - PubMed
  17. Ann Hum Genet. 2017 Jul;81(4):141-146 - PubMed
  18. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  19. Br J Ophthalmol. 2015 Sep;99(9):1301-5 - PubMed
  20. Mol Genet Genomic Med. 2020 Oct;8(10):e1466 - PubMed
  21. J Diabetes Complications. 2010 May-Jun;24(3):192-8 - PubMed
  22. Mol Vis. 2014 May 27;20:704-13 - PubMed
  23. J Immunol. 2006 Jul 1;177(1):322-32 - PubMed
  24. Curr Diab Rep. 2017 Sep;17(9):72 - PubMed
  25. Genet Mol Res. 2015 Jul 31;14(3):8694-705 - PubMed
  26. Biomed Res Int. 2013;2013:318686 - PubMed
  27. Gene. 2018 Jan 30;641:196-202 - PubMed
  28. Scand J Immunol. 2012 May;75(5):517-23 - PubMed
  29. Diabetes Metab Syndr Obes. 2020 Apr 03;13:1015-1021 - PubMed
  30. Endocr Regul. 2017 Jul 1;51(3):137-144 - PubMed
  31. Am Heart J. 2004 Dec;148(6):1034-40 - PubMed
  32. Yonsei Med J. 2008 Feb 29;49(1):58-62 - PubMed
  33. Genome Biol. 2002 Jul 29;3(8):REVIEWS3011 - PubMed
  34. Cell. 2006 Feb 24;124(4):783-801 - PubMed
  35. Nat Rev Endocrinol. 2011 Nov 08;8(4):228-36 - PubMed
  36. J Immunol. 2002 Jan 15;168(2):554-61 - PubMed
  37. PeerJ. 2014 Sep 30;2:e605 - PubMed

Substances

MeSH terms

Publication Types